Trials / Terminated
TerminatedNCT02326740
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | gevokizumab | |
| DRUG | Placebo | |
| DRUG | gevokizumab open-label |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2014-12-29
- Last updated
- 2016-04-27
Locations
16 sites across 3 countries: United States, Australia, Canada
Source: ClinicalTrials.gov record NCT02326740. Inclusion in this directory is not an endorsement.